William Blair analyst Ryan Daniels has maintained their bullish stance on EVH stock, giving a Buy rating yesterday.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Ryan Daniels has given his Buy rating due to a combination of factors including the recent modest revisions to Evolent Health’s financial model following their first-quarter earnings. The adjustments primarily involved a shift in the quarterly sales forecast for 2025, moving some revenue from the fourth quarter to the third quarter, while maintaining the overall annual outlook. The sales estimates for 2026 remain largely unchanged, reflecting confidence in the company’s long-term growth trajectory.
Additionally, Ryan Daniels slightly increased the adjusted EBITDA estimate for 2025 to align with the guidance midpoint, indicating a positive outlook on the company’s profitability. The earnings per share estimates were also adjusted, showing an increase for both 2025 and 2026, which suggests an expectation of improved financial performance. These factors collectively support the Buy rating, as they demonstrate a stable and promising financial future for Evolent Health.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $15.00 price target.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EVH in relation to earlier this year.